Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036726 | 0.73 | RAPGEF4 (0.49) | RAPGEF4MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL1032803 | 0.72 | NPC1 (0.45) | RAPGEF4MEN1KMT2AHPGDGAA | |
| SCHEMBL2458090 | 0.69 | MEN1 (0.47) | RAPGEF4MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL15188815 | 0.69 | RAPGEF4 (1.00) | RAPGEF4 | |
| SCHEMBL9516537 | 0.68 | HPGD (0.78) | RAPGEF4MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL50079 | 0.68 | HPGD (0.78) | RAPGEF4MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL108881 | 0.68 | HPGD (0.78) | RAPGEF4MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL18591961 | 0.68 | KMT2A (0.52) | RAPGEF4MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL12470477 | 0.68 | L3MBTL1 (0.46) | RAPGEF4MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL14318533 | 0.68 | MEN1 (0.46) | RAPGEF4MEN1KMT2ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906677-B2 | Process for phenylacetic acid derivatives | NOVARTIS AG (CH) | 2011-03-15 | — | — | US | disclosed |
| US-7906677-B2 | Process for phenylacetic acid derivatives | NOVARTIS AG (CH) | 2011-03-15 | — | — | US | disclosed |
| US-7906677-B2 | Process for phenylacetic acid derivatives | NOVARTIS AG (CH) | 2011-03-15 | — | — | US | disclosed |
| EP-2275403-A1 | Process for phenylacetic acid derivatives | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20090275758-A1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
| US-20090275758-A1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
| US-20090275758-A1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-05 | — | — | US | disclosed |
| EP-1216226-B1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-04 | — | — | EP | disclosed |
| EP-1216226-B1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2009-11-04 | — | — | EP | disclosed |
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ACEMOGLU MURAT | 2008-10-09 | — | — | US | disclosed |
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ACEMOGLU MURAT | 2008-10-09 | — | — | US | disclosed |
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ACEMOGLU MURAT | 2008-10-09 | — | — | US | disclosed |
| EP-1216226-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | Novartis AG (CH) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023346-A2 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249318-A1 | Process for phenylacetic acid derivatives | ALDH7A1, CYP4F11, CYP2A6 | RAPGEF4 1844/4885MEN1 2959/4885KMT2A 1314/4885 |
| US-20090275758-A1 | PROCESS FOR PHENYLACETIC ACID DERIVATIVES | ALDH7A1, CYP4F11, CYP2A6 | RAPGEF4 1844/4885MEN1 2959/4885KMT2A 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.